Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von Letue35 

Discuss Cytokinetics Inc.

Cytokinetics Inc.

WKN: A1W1KK / Symbol: CYTK / Name: Cytokinetics / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

54,00 €
3,85 %

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 19,21 %
Kursziel 115,06
Veränderung
Endet am 21.01.26

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 20,00 %
Kursziel 76,65
Veränderung
Endet am 22.01.26

Cytokinetics, Incorporated (NASDAQ: CYTK) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $80.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 21,08 %
Kursziel 69,25
Veränderung
Endet am 06.02.26

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 23,29 %
Kursziel 82,96
Veränderung
Endet am 07.02.26

Cytokinetics, Incorporated (NASDAQ: CYTK) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $86.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Cytokinetics, Incorporated (NASDAQ: CYTK) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 31,71 %
Kursziel 64,45
Veränderung
Endet am 13.02.26

Cytokinetics, Incorporated (NASDAQ: CYTK) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $67.00 price target on the stock, down previously from $70.00.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 21,62 %
Kursziel 115,28
Veränderung
Endet am 28.02.26

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 56,98 %
Kursziel 108,43
Veränderung
Endet am 04.04.26

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 57,89 %
Kursziel 65,70
Veränderung
Endet am 08.04.26

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 57,89 %
Kursziel 105,97
Veränderung
Endet am 15.04.26

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 63,64 %
Kursziel 104,57
Veränderung
Endet am 21.04.26

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 60,71 %
Kursziel 48,44
Veränderung
Endet am 24.04.26

Cytokinetics, Incorporated (NASDAQ: CYTK) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $55.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 74,19 %
Kursziel 63,75
Veränderung
Endet am 02.05.26

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 83,67 %
Kursziel 70,52
Veränderung
Endet am 07.05.26

Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at Citigroup Inc. from $86.00 to $80.00. They now have a "buy" rating on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 83,67 %
Kursziel 70,52
Veränderung
Endet am 07.05.26

Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at Royal Bank of Canada from $82.00 to $80.00. They now have an "outperform" rating on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 86,21 %
Kursziel 46,79
Veränderung
Endet am 08.05.26

Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at Barclays PLC from $55.00 to $53.00. They now have an "overweight" rating on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 100,00 %
Kursziel 64,35
Veränderung
Endet am 14.05.26

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 98,53 %
Kursziel 74,65
Veränderung
Endet am 29.05.26

Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at Mizuho from $103.00 to $84.00. They now have an "outperform" rating on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 86,21 %
Kursziel 46,41
Veränderung
Endet am 09.06.26

Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at JPMorgan Chase & Co. from $71.00 to $53.00. They now have an "overweight" rating on the stock.
Ratings data for CYTK provided by MarketBeat